An 81-year-old woman with well-controlled hypertension presented to the emergency
department with new-onset atrial fibrillation with rapid ventricular response. Treatment for …

An 81-year-old woman with well-controlled hypertension presented to the emergency
department with new-onset atrial fibrillation with rapid ventricular response. Treatment for …

The hepatobiliary effects of direct oral anticoagulants (DOACs) have been under close
surveillance since hepatotoxicity was demonstrated with ximelagatran during the post …

Apixaban is a selective and reversible coagulation factor Xa inhibitor that indirectly inhibits
the platelet coagulation reaction induced by thrombin. It is for reducing stroke and …

Apixaban is widely used to prevent and manage thromboembolic disease. Due to it being
fairly new in the market, we are still understanding its complete risk profile. We present a …

Apixaban is widely used to prevent and manage thromboembolic disease. Due to it being
fairly new in the market, we are still understanding its complete risk profile. We present a …

A 72-year-old woman developed hepatotoxicity during treatment with apixaban [route not
stated]. The woman was admitted for pacemaker implantation for sinus node dysfunction …

Rivaroxaban is a commonly used anticoagulant agent for treatment and prevention of
thromboembolism. There are case reports demonstrating an association between its use …

Apixaban is a direct oral anticoagulant (DOAC) that acts on the coagulation cascade by
direct factor Xa inhibition. It is currently approved for the prevention and treatment of venous …

The use of new oral anticoagulants such as apixaban is increasing. We present the case of
an 85-year-old patient who was diagnosed with mixed profile toxic hepatitis due to apixaban …